bispecific – Talk Bio

Actionable Insights Powered by AI

Cullinan Inks $700M Deal for BCMA Bispecific to Expand Autoimmune T-Cell Engager Portfolio

3 days ago talkbio0Tagged Autoimmune Diseases, biotech partnerships, bis(3-bis(4-chlorophenyl)methyl-4-dimethylaminophenyl)amine, bispecific, CD19xCD3, Clinical Development, CLN-978, Cullinan, Genrix Bio, Multiple Myeloma, T-Cell engager, velinotamig

Cullinan Therapeutics; Genrix Bio; BCMA bispecific; velinotamig; T-cell engager; autoimmune disease; CD19xCD3; CLN-978; multiple myeloma; clinical development; biotech partnerships

BioNTech Invests $800M in PD-L1xVEGF-A Bispecific, Aiming to Challenge Keytruda Dominance

7 months ago talkbio0Tagged BioNTech, Biotheus, bispecific, Drug Industry, Immunotherapy for cancer, Keytruda, PD-L1xVEGF-A

BioNTech, Keytruda, PD-L1xVEGF-A bispecific, Biotheus, cancer immunotherapy, pharmaceutical industry